BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 52-Week High – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $10.48 and last traded at $10.6090, with a volume of 1360689 shares. The stock had previously closed at $10.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BCRX shares. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Needham & Company LLC cut their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Citizens Jmp raised their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.70.

BioCryst Pharmaceuticals Stock Performance

The business has a 50 day simple moving average of $8.88 and a 200-day simple moving average of $8.23. The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of -5.72 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same period in the previous year, the firm posted $0.20 EPS. The company’s revenue was up 7.5% compared to the same quarter last year. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds have recently made changes to their positions in BCRX. Phocas Financial Corp. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $1,956,000. Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 6.1% during the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after acquiring an additional 1,246,633 shares during the last quarter. Aberdeen Group plc acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter worth $7,126,000. BNP Paribas Financial Markets raised its position in BioCryst Pharmaceuticals by 21.4% in the fourth quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock valued at $19,833,000 after purchasing an additional 448,436 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in BioCryst Pharmaceuticals by 106.5% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock valued at $1,820,000 after purchasing an additional 120,350 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.